Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endothelial Cell-Targeted Deletion of PPARγ Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue.
Akiyama TE, Skelhorne-Gross GE, Lightbody ED, Rubino RE, Shi JY, McNamara LA, Sharma N, Zycband EI, Gonzalez FJ, Liu H, Woods JW, Chang CH, Berger JP, Nicol CJB. Akiyama TE, et al. Among authors: lightbody ed. J Pharmacol Exp Ther. 2019 Mar;368(3):514-523. doi: 10.1124/jpet.118.250985. Epub 2019 Jan 3. J Pharmacol Exp Ther. 2019. PMID: 30606762 Free PMC article.
An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications.
Dasgupta A, Chen KH, Wu D, Hoskin V, Mewburn J, Lima PDA, Parlow LRG, Hindmarch CCT, Martin A, Sykes EA, Tayade C, Lightbody ED, Madarnas Y, SenGupta SK, Elliott BE, Nicol CJB, Archer SL. Dasgupta A, et al. Among authors: lightbody ed. FASEB J. 2020 Apr;34(4):5106-5127. doi: 10.1096/fj.201903117R. Epub 2020 Feb 18. FASEB J. 2020. PMID: 32068312
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N, Li D, Conseil G, Lightbody ED, Wilson-Sanchez J, Hamade A, Chenard S, Jawa NA, Laight BJ, Afriyie-Asante A, Tyryshkin K, Koebel M, Koti M. Shakfa N, et al. Among authors: lightbody ed. J Immunother Cancer. 2023 Apr;11(4):e006170. doi: 10.1136/jitc-2022-006170. J Immunother Cancer. 2023. PMID: 37015760 Free PMC article.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, Kumar SK. Anderson KC, et al. Clin Cancer Res. 2021 Oct 1;27(19):5195-5212. doi: 10.1158/1078-0432.CCR-21-1059. Clin Cancer Res. 2021. PMID: 34321279 Free PMC article.
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Konishi Y, Sklavenitis-Pistofidis R, Yue H, Ferrari F, Redd RA, Lightbody ED, Russo M, Perry J, Horowitz E, Justis AV, Shayegh NA, Savell A, Prescott J, Varmeh S, Nowak RP, Hamilton M, Auclair D, Marinac CR, Trippa L, Fischer ES, Ghobrial IM. Konishi Y, et al. Among authors: lightbody ed. Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9. Cancer Cell. 2022. PMID: 34895486 Free PMC article. No abstract available.
17 results